Followers | 827 |
Posts | 119581 |
Boards Moderated | 14 |
Alias Born | 09/05/2002 |
Saturday, July 23, 2011 12:35:16 PM
#msg-65423443
From a technical standpoint, Xeomin is an excellent product, superior to both Botox and Dysport; hence, the limiting factor on Xeomin’s attaining market share is Merz’s low-key marketing (compared to AGN and MRX) and the brand-name loyalty of Botox and Dysport users.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent MRX News
- Marex Group plc Announces Pricing of Initial Public Offering • GlobeNewswire Inc. • 04/25/2024 01:33:37 AM
- Marex Group plc Announces Launch of Initial Public Offering • GlobeNewswire Inc. • 04/15/2024 01:19:28 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM